Table 2 SVF cell therapy and outcomes
Case | Age/gender | Diagnosis | Cells (mln.) administered per procedure (numbers of procedure) | Time after procedure (months) | Clinical symptom, ulcer healing | Claudication (m) | ABI improvement (%) |
|---|---|---|---|---|---|---|---|
1 (L) | 35/M | ASO | 40 (2) | 12 | Improved, ulcer healed | 500–600 | 48 |
2 (R) | 70/M | ASO | 56 (2) | 12 | Improved | 300–350 | 23 |
3 (L) | 68/M | ASO | 32 (1) | 12 | Improved | 250–300 | 18 |
4 (L) | 52/M | ASO | 55 (2) | 12 | Improved | 400–450 | 40 |
5 (R) | 59/M | ASO | 38 (2) | 12 | Improved | 300–350 | 35 |
6 (Lu) | 77/F | ASO | 45 (2) | 12 | Improved | – | – |
7 (L) | 77/F | ASO | 42 (1) | 12 | Improved, ulcer healed | 150–200 | 17 |
8 (R) | 67/M | ASO | 56 (2) | 12 | Improved, ulcer healed | 200–250 | 29 |
9 (L) | 60/F | ASO | 36 (2) | 12 | Improved | 300–350 | 37 |
10 (R) | 68/F | ASO | 32 (1) | 1 week | Major amputation, wound healed | – | – |
11 (L) | 60/M | ASO | 43 (2) | 12 | Improved, ulcer healed | 300–350 | 25 |
12 (R) | 56/M | ASO | 51 (1) | 12 | Improved, ulcer healed | 300–350 | 23 |
13 (L) | 67/M | ASO | 39 (2) | 12 | Improved | 300–350 | 28 |
14 (R) | 72/F | ASO | 33 (1) | 12 | Improved | 250–300 | 25 |
15 (R) | 64/M | ASO | 34 (1) | 2 weeks | Major amputation, wound healed | – | – |